<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165176</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00035394</org_study_id>
    <nct_id>NCT02165176</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis</brief_title>
  <official_title>Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Substance Abuse and Mental Health Services Administration (SAMHSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Few studies have been conducted to assess the pharmacokinetic and pharmacodynamic effects of&#xD;
      orally consumed intact cannabis (e.g., cannabis-containing brownies). Careful analysis of&#xD;
      oral cannabis dose effects on these parameters is required to determine the level and&#xD;
      duration of biological cannabinoid exposure and associated subjective, cardiovascular and&#xD;
      cognitive effects. In the present study we evaluated the detection of cannabinoids in oral&#xD;
      fluid, plasma, hair, and urine for up to 9 days following consumption of oral cannabis (10mg,&#xD;
      25mg, or 50mg THC). The outcomes of the study will extend scientific knowledge about the&#xD;
      behavioral pharmacology and toxicology of oral cannabis administration and can inform&#xD;
      policies regarding clinical, workplace and roadside drug testing programs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood THC</measure>
    <time_frame>baseline and 0.2, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 22, 26, 30, 34, 46, 50, 54, 58, 70, 74, 78, 82, 94, 98, 102, 106, 118, 122, 126, and 130 hours post exposure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine THC-COOH</measure>
    <time_frame>Baseline and 1, 2, 3, 4, 4-6 hours, 6-8 hours, 8-10 hours, 10-12 hours and then every 4 hours up until the 130 hour post exposure time point</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Fluid THC</measure>
    <time_frame>baseline and 0.2, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 22, 26, 30, 34, 46, 50, 54, 58, 70, 74, 78, 82, 94, 98, 102, 106, 118, 122, 126, and 130 hours post exposure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective rating of &quot;Drug Effect&quot;</measure>
    <time_frame>baseline, immediately after exposure and 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post exposure</time_frame>
    <description>Visual analog scale ratings of subjective intoxication</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cannabis</condition>
  <arm_group>
    <arm_group_label>10mg acute oral cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg acute oral cannabis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mg acute oral cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg acute oral cannabis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg acute oral cannabis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg acute oral cannabis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral cannabis</intervention_name>
    <arm_group_label>10mg acute oral cannabis</arm_group_label>
    <arm_group_label>25mg acute oral cannabis</arm_group_label>
    <arm_group_label>50mg acute oral cannabis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have provided written informed consent&#xD;
&#xD;
          2. Be between the ages of 18 and 45&#xD;
&#xD;
          3. Be in good general health based on a physical examination, medical history, vital&#xD;
             signs, 12-lead ECG and screening urine and blood tests&#xD;
&#xD;
          4. Test negative for recent cannabis use in urine at the screening visit (confirmed by&#xD;
             GC/MS laboratory test) and at clinic admission&#xD;
&#xD;
          5. Test negative for other drugs of abuse, including alcohol at the screening visit and&#xD;
             at clinic admission&#xD;
&#xD;
          6. Demonstrate ability to expectorate 3-5 mL of &quot;native&quot; oral fluid over a 5-minute&#xD;
             period&#xD;
&#xD;
          7. Not be pregnant or nursing (if female). All females must have a negative serum&#xD;
             pregnancy test at the screening visit and a negative urine pregnancy test at clinic&#xD;
             admission.&#xD;
&#xD;
          8. Have a body mass index (BMI) in the range of 19 to 36 kg/m2&#xD;
&#xD;
          9. Have head hair that is at least 4 cm (approximately one and a half inches) in length&#xD;
             on the back of the head.&#xD;
&#xD;
         10. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of&#xD;
             150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg&#xD;
&#xD;
         11. Have no allergies to any of the ingredients used to prepare cannabis brownies&#xD;
             (chocolate, eggs, wheat, etc.).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3&#xD;
             month prior to the Screening Visit;&#xD;
&#xD;
          2. History of or current evidence of significant medical or psychiatric illness judged by&#xD;
             the investigator to put the participant at greater risk of experiencing an adverse&#xD;
             event due to exposure or completion of other study procedures.&#xD;
&#xD;
          3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within&#xD;
             14 days of experimental sessions; which, in the opinion of the investigator or&#xD;
             sponsor, will interfere with the study result or the safety of the subject.&#xD;
&#xD;
          4. Use of a prescription medication (with the exception of birth control prescriptions)&#xD;
             within 14 days of experimental sessions; which, in the opinion of the investigator or&#xD;
             sponsor, will interfere with the study result or the safety of the subject.&#xD;
&#xD;
          5. Use of hemp seeds or hemp oil in any form in the past 3 months.&#xD;
&#xD;
          6. Use of dronabinol (Marinol) within the past 6 months.&#xD;
&#xD;
          7. History of xerostomia (dry mouth), or the presence of mucositis, gum infection or&#xD;
             bleeding, or other significant oral cavity disease or disorder that in the&#xD;
             investigator's opinion may affect the collection of oral fluid samples.&#xD;
&#xD;
          8. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g.,&#xD;
             Prinzmetal's angina).&#xD;
&#xD;
          9. Abnormal EKG result that in the investigator's opinion is clinically significant.&#xD;
&#xD;
         10. Enrolled in another clinical trial or have received any drug as part of a research&#xD;
             study within 30 days prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Ryan Vandrey</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>toxicology</keyword>
  <keyword>intoxication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

